NASDAQ · Biotechnology
CBIO (CBIO) Stock
$16.84
+2.50%
NASDAQ: CBIO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Crescent Biopharma Closes $143.7 Million Public Offering
MT Newswires · Jul 16, 2026
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire · Jul 16, 2026
Crescent Biopharma Prices $125 Million Common, Warrant Offering
MT Newswires · Jul 15, 2026
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire · Jul 15, 2026
Crescent Biopharma Launches Offering of Common Shares, Warrants
MT Newswires · Jul 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.44%
Institutions Held77.62%
Institutions Float Held77.96%
Peer Comparison
About CBIO
CBIO is led by CEO Joshua T. Brumm, employs 41 people, headquartered in US, publicly traded since 2014.
CBIO stock trades at $16.84 with a market capitalization of $625.50M. The stock is valued at a price-to-earnings (P/E) ratio of -6.03, price-to-book of 3.28, price-to-sales of 41.17. Over the past 52 weeks the stock has ranged between $8.72 and $27.41, and currently trades 38.6% below its 52-week high.
On profitability, CBIO generates a return on equity (ROE) of -75.86%, return on capital employed of -75.37%, an operating margin of -13.73%, a net profit margin of -13.64%.